ABSTRACT
Introduction Asymptomatic testing for SARS-CoV-2 among healthcare workers or other essential personnel could remove infected carriers from the workforce, decreasing chances for transmission and workplace outbreaks. Results from one-time testing programs have been reported but data regarding longitudinal testing, including information about employee’s reactions to such programs, is not readily available.
Methods To identify asymptomatic carriers of SARS-CoV-2, we implemented a longitudinal screening program for critical on-site employees within our research institute in early April 2020. We conducted a survey of both on-site employees and those working from home in order to measure their reactions to the testing program. Statistical analysis of the survey was conducted with general linear regression and Pearson’s Chi-Square tests.
Results Despite an ongoing high community prevalence rate of COVID-19, to date only two asymptomatic employees tested positive out of 1050 tests run during 7 months of the program. However, 12 symptomatic employees not participating in the program have tested positive. The employee survey was completed by 132/306 (43%) employees, with 93% agreeing that asymptomatic employee screening led to a better and safer working environment and 75% agreeing with on-site public health measures to help contain the virus, but only 58% feeling COVID-19 was a serious threat to their health.
Conclusion Our results suggest that a longitudinal asymptomatic employee screening program for SARS-CoV-2 can be accepted by employees and can be used to maintain the health of the workforce, potentially keeping positivity rates below community levels in the face of the ongoing COVID-19 pandemic.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Aspects of this work were funded in part by philanthropic gifts from the Northern Arizona Regional Behavioral Health Authority (NARBHA) Institute and the Garcia Family Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Western IRB was consulted and confirmed this study was exempt from IRB review.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Financial disclosures: The authors have no financial disclosures or conflicts of interest.
Data Availability
The data is available from the authors upon request.
